Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer

被引：10
|
作者：
Kaisary, AV [1 ]
机构：
[1] Royal Free Hosp, Dept Urol, London NW3 2QG, England
来源：
PROSTATE CANCER AND PROSTATIC DISEASES | 2005年 / 8卷 / 02期
关键词：
prostate cancer; hormonal therapy; castration; luteinising hormone-releasing hormone agonist; nonsteroidal antiandrogen;
D O I：
10.1038/sj.pcan.4500800
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
This article evaluates the use of early hormonal therapy in patients with localised or locally advanced prostate cancer. In patients receiving radiotherapy, an overall survival benefit is proven for adjuvant goserelin ('Zoladex') in locally advanced disease. Adjuvant to radical prostatectomy, castration ( goserelin or orchiectomy) has demonstrated an overall survival benefit in patients with lymph node metastases. Survival advantages have not yet been proven with nonsteroidal antiandrogens, but immediate or adjuvant bicalutamide ('Casodex') improves objective progression-free survival in patients with locally advanced disease, with certain quality-of-life advantages over castration.
引用
收藏
页码：140 / 151
页数：12
相关论文
共 50 条
  • [11] Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer
    Hatoum, Hind T.
    Crawford, E. David
    Nielsen, Sandy Kildegaard
    Lin, Swu-Jane
    Marshall, Dennis C.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2013, 13 (02) : 261 - 270
  • [12] Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: Results from the randomised Early Prostate Cancer Programme
    Tyrrell, CJ
    Payne, H
    See, WA
    McLeod, DG
    Wirth, MP
    Iversen, P
    Armstrong, J
    Morris, C
    RADIOTHERAPY AND ONCOLOGY, 2005, 76 (01) : 4 - 10
  • [13] Guideline of guidelines: primary monotherapies for localised or locally advanced prostate cancer
    Lancee, Michelle
    Tikkinen, Kari A. O.
    de Reijke, Theo M.
    Kataja, Vesa V.
    Aben, Katja K. H.
    Vernooij, Robin W. M.
    BJU INTERNATIONAL, 2018, 122 (04) : 535 - 548
  • [14] Early versus late hormonal therapy for prostate cancer
    Miyamoto H.
    Messing E.M.
    Current Urology Reports, 2004, 5 (3) : 188 - 196
  • [15] Novel secondary hormonal therapy in advanced prostate cancer: an update
    Van Allen, Eliezer M.
    Ryan, Charles J.
    CURRENT OPINION IN UROLOGY, 2009, 19 (03) : 315 - 321
  • [16] Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer
    Bolla, M
    EUROPEAN UROLOGY, 1999, 35 : 23 - 25
  • [17] The comparison of outcomes between neoadjuvant novel and classical hormonal therapy in patients with locally advanced prostate cancer: a retrospective study
    Zhen Yang
    Yang Liu
    Yuan Shao
    Yudong Wu
    Yong Wang
    Jianing Guo
    Zihao Liu
    Hua Huang
    Jing Tian
    Yuanjie Niu
    Simeng Wen
    BMC Urology, 25 (1)
  • [18] The current status of adjuvant hormonal therapy combined with radiation therapy for localised prostate cancer
    J. Armstrong
    Irish Journal of Medical Science, 1998, 167 : 138 - 144
  • [19] The use of Hormonal Therapy to Augment Radiation Therapy in Prostate Cancer: An Update
    Kauffmann, Greg
    Liauw, Stanley L.
    CURRENT UROLOGY REPORTS, 2017, 18 (07)
  • [20] The use of Hormonal Therapy to Augment Radiation Therapy in Prostate Cancer: An Update
    Greg Kauffmann
    Stanley L. Liauw
    Current Urology Reports, 2017, 18
12345